US20190201463A1 – July 4, 2019 – COMPOUND AND METHOD FOR TREATMENT OF MOVEMENT DISORDERS

Please complete the required fields.




Inventors :

Alexander Kariman

Owner :

MMJ BioScience, Inc.

Application Number :

US15859692

Document Number :

US20190201463A1

Priority Date :

January 1, 2018

Filing Date :

January 1, 2018

Date of Grant/ Publication :

July 4, 2019

Class :

A61K36 / 185; A61K47 / 44; A61K9 / 48; A61K9 / 20; A61K9 / 00; A61P25 / 16; A61P25 / 32

Abstract

The disclosed invention generally relates to pharmaceutical compounds and methods for treating and/or preventing diseases and disorders that often manifest in hyper and/or hypokinetic movements symptoms, as well as the method of administering therapeutically-effective amount of a pharmaceutical compound containing cannabinoids to subjects in need of treatment. The disclosed invention further relates to cannabinoid pharmaceutical compounds where said compound contains at least some non-cannabinoid components.

Claim(s)

1 . A method of treating and/or preventing diseases and disorders that manifest in hyper and hypokinetic movements symptoms in subjects in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a pharmaceutical compound one or more times in 24 hours, comprising of an extract of a Cannabis plant and at least one pharmacologically inactive substance; and where said extract contains at least some tetrahydrocannabinol (THC) isomer and at least some cannabidiol (CBD) isomer in the ratio of 1 (THC) and 2 (CBD) by weight; and where said compound contains at least some non-cannabinoid components consisting essentially of at least one of: terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids.;
14 . A pharmaceutical compound for treating and/or preventing diseases and disorders that manifest in hyper and hypokinetic movements symptoms in subjects in need thereof, comprising of an extract of Cannabis and at least one pharmacologically inactive substance; and where said extract contains at least some tetrahydrocannabinol (THC) isomer and at least some cannabidiol (CBD) isomer in the ratio of 1 (THC) and 2 (CBD) by weight; and where said compound contains at least some non-cannabinoid components consisting essentially of at least one of: terpenes; sterols; triglycerides; alkanes; squalene; tocopherol; carotenoids; chlorophyll; flavonoid; glycosides and alkaloids.;
27 . A pharmaceutical compound for treating and/or preventing cannabinoid-responsive diseases and disorders, comprising of a Cannabis extract or a compound containing at least 10% of natural or synthetic, or semi-synthetic tetrahydrocannabinol (THC), its prodrug, its derivative, or its analog, and at least one pharmacologically inactive substance; and where said compound is packaged in a gelatin capsule, where said capsule does not contain lambda-carrageenan, kappa-carrageenan, iota-carrageenan and any mixture of the carrageenans.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login